Antisense modulation of caspase 9 expression
First Claim
Patent Images
1. A compound up to 50 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO:
- 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 60, 61, 62, 63, 64, 65, 66, 67, 68, 70, 71, 72, 73, 74, 75, 76, 77, 78, 80, 81, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 100, 101, 102, 103, 105, 106, 108, 109, 110, 111, 112, 113, 114, 116, 117, 118, 122, 124, 125, 126, 127, 128, 129, 131, 132, 133, 134, 135, 136, 137, 139, 140, 141, 143, 144, 145, 146, 147, 150, 152, 154, 155, 156, 157, 158, 159, 161, 162, 163, 164, 165, 166, 168, 169, 170, 171, 172, 173 or 174 which inhibits the expression of caspase 9.
1 Assignment
0 Petitions
Accused Products
Abstract
Antisense compounds, compositions and methods are provided for modulating the expression of caspase 9. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding caspase 9. Methods of using these compounds for modulation of caspase 9 expression and for treatment of diseases associated with expression of caspase 9 are provided.
-
Citations
13 Claims
-
1. A compound up to 50 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO:
- 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 60, 61, 62, 63, 64, 65, 66, 67, 68, 70, 71, 72, 73, 74, 75, 76, 77, 78, 80, 81, 83, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 100, 101, 102, 103, 105, 106, 108, 109, 110, 111, 112, 113, 114, 116, 117, 118, 122, 124, 125, 126, 127, 128, 129, 131, 132, 133, 134, 135, 136, 137, 139, 140, 141, 143, 144, 145, 146, 147, 150, 152, 154, 155, 156, 157, 158, 159, 161, 162, 163, 164, 165, 166, 168, 169, 170, 171, 172, 173 or 174 which inhibits the expression of caspase 9.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
Specification